Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Investment Income: 2020-2025

Historic Investment Income for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to -$9.0 million.

  • Pharming Group N.V's Investment Income fell 411.72% to -$9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 511.11%. This contributed to the annual value of -$6.1 million for FY2024, which is 203.57% down from last year.
  • Latest data reveals that Pharming Group N.V reported Investment Income of -$9.0 million as of Q3 2025, which was down 134.37% from $26.1 million recorded in Q2 2025.
  • Pharming Group N.V's Investment Income's 5-year high stood at $26.1 million during Q2 2025, with a 5-year trough of -$11.6 million in Q3 2022.
  • For the 3-year period, Pharming Group N.V's Investment Income averaged around $1.6 million, with its median value being -$100,000 (2023).
  • Within the past 5 years, the most significant YoY rise in Pharming Group N.V's Investment Income was 25,439.68% (2022), while the steepest drop was 37,811.12% (2022).
  • Over the past 5 years, Pharming Group N.V's Investment Income (Quarterly) stood at -$63,000 in 2021, then spiked by 25,439.68% to $16.0 million in 2022, then crashed by 100.63% to -$100,000 in 2023, then tumbled by 4,672.00% to -$4.8 million in 2024, then tumbled by 411.72% to -$9.0 million in 2025.
  • Its Investment Income stands at -$9.0 million for Q3 2025, versus $26.1 million for Q2 2025 and $8.9 million for Q1 2025.